In a phase I clinical trial (NCT01593696), a dose-escalation experiment was conducted to study treatment of children and young adult patients with ALL and non-Hodgkin’s lymphoma (NHL) with autologous transfusion of doses of 1.0 × 106/kg (dose 1) or 3.0 × 106/kg (dose 2) CD19 CAR-T cells (117). Here, CD19 is linked to non-Hodgkin lymphoma.